Ruifu Chemical Supply Ivabradine Hydrochloride Intermediates With High Purity
Ivabradine Hydrochloride CAS 148849-67-6
4,5-Dimethoxy-1-Cyanobenzocyclobutane CAS 35202-54-1
(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane Hydrochloride CAS 866783-13-3
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one CAS 73942-87-7
7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one CAS 148870-57-9
3-(3-Chloropropyl)-7,8-dimethoxy-1H-3-benzazepin-2(3H)-one CAS 85175-59-3
| Chemical Name | 4,5-Dimethoxy-1-Cyanobenzocyclobutane |
| Synonyms | 4,5-Dimethoxy-1-Benzocyclobutenecarbonitrile; 1-Cyano-4,5-Dimethoxybenzocyclobutene; 3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-Carbonitrile; Ivabradine Hydrochloride Intermediate |
| CAS Number | 35202-54-1 |
| CAT Number | RF-PI1809 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C11H11NO2 |
| Molecular Weight | 189.21 |
| Melting Point | 83.0~84.0℃ |
| Density | 1.18 |
| Solubility (Soluble in) | Methanol |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | Off-White to Light Brown Powder |
| Identification | HPLC/UV Complies |
| Purity / Analysis Method | >99.0% (HPLC) |
| Loss on Drying | <0.50% (Dry it at 40℃ till constant weight ) |
| Residue on Ignition | <0.10% |
| Related Substances | |
| Individual Impurity | <0.50% |
| Total Impurities | <1.00% |
| Heavy Metals | <10ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Ivabradine Hydrochloride (CAS: 148849-67-6) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
4,5-Dimethoxy-1-Cyanobenzocyclobutane (CAS: 35202-54-1) is an intermediate of Ivabradine Hydrochloride (CAS: 148849-67-6). Ivabradine Hydrochloride has evolved as a specific inhibitor of If current through its contact with f-channels on the intracellular side of the plasma membrane. As a consequence, Ivabradine reduces the speed of diastolic depolarization and decreases heart rate. It has been approved for the treatment of chronic stable angina and provides a viable alternative to patients with a contraindication or intolerance of b-blockers. Evaluation is also underway for the potential treatment of ischemic heart disease.